No profile data available.
Atossa Therapeutics, Inc. (ATOS) is a healthcare company in the breast cancer treatment drugs industry, based in Seattle, United States, with about 16 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$34.77 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $24.35 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
Atossa Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$24.35 million as of October 9, 2026.
Listed companies of a similar size in the same industry (breast cancer treatment drugs) include Greenwich LifeSciences, Inc. (GLSI), Odonate, Inc. (ODTC), BriaCell Therapeutics Corp. (BCTX).